Vir Biotechnology, Inc. (VIR) FY2025 10-K Annual Report
Vir Biotechnology, Inc. (VIR) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 23, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Vir Biotechnology, Inc. FY2025 10-K Analysis
Business Overview
- • Core business model focused on development and commercialization of infectious disease therapeutics
- • New clinical programs highlighted: Phase 1 study of VIR-5525 and CHD ECLIPSE registrational program initiated with $125.5M milestone payments in 2025
Management Discussion & Analysis
- • Revenue $114.8M for FY 2025, down from $129.4M in FY 2024, a 11.3% decrease
- • Operating loss $354.7M in FY 2025 vs loss $348.0M in FY 2024, operating margin negative, slight deterioration
Risk Factors
- • Regulatory risk from FDA revocation of sotrovimab EUA in Dec 2024, limiting near-term revenue generation from key product candidate
- • Geopolitical risk due to patient enrollment challenges in clinical trials in countries affected by civil or political unrest
Vir Biotechnology, Inc. FY2025 Key Financial MetricsXBRL
Revenue
$69M
▼ -7.6% YoY
Net Income
-$438M
▲ +16.1% YoY
Operating Margin
-699.2%
▲ +9210bp YoY
Net Margin
-638.9%
▲ +6453bp YoY
ROE
-57.2%
▼ -1186bp YoY
Total Assets
$1.0B
▼ -28.3% YoY
EPS (Diluted)
$-3.16
▲ +17.5% YoY
Operating Cash Flow
-$392M
▲ +12.2% YoY
Source: XBRL data from Vir Biotechnology, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Vir Biotechnology, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.